The product described is (1S,2S)-2-amino-1-(4-nitrophenyl)propane-1,3-diol, molecular formula C9H12N2O4, molecular weight 212.20 g/mol, supplied as a pharmaceutical-grade active pharmaceutical ingredient in free-base form. The grade is intended for tablet, capsule, granule, and injectable manufacture; separate oral and injectable release grades are differentiated by particle-size distribution, bioburden, bacterial endotoxin, residual solvent profile, and subvisible particulate control. The chiral molecule contains two stereogenic centres and is supplied as the single (1S,2S) isomer; release testing therefore includes chiral chromatographic separation from the (1R,2R) antipode and the erythro diastereomers. The certificate of analysis is structured under ICH Q6A decision-tree guidance and reports appearance, infrared identification, specific optical rotation, assay by HPLC, related substances, water content, residue on ignition, residual solvents according to ICH Q3C, elemental impurities according to ICH Q3D, enantiomeric purity, and—for injectable grade—bacterial endotoxins and particulate matter. The primary aliphatic amine confers pH-dependent aqueous solubility; the nitrophenyl group limits photostability and requires light-protective storage. The substance is not a racemic mixture, not a hydrochloride salt, and not a direct substitute for the (1R,2R) chloramphenicol base.

Orderable grades are designated by the manufacturer’s lot-specific coding system: oral milled grade for dry blending and granulation, injectable low-endotoxin grade for aseptic solution preparation, and optionally micronized grade where dissolution or syringeability requires particle-size reduction. Packaging is typically double polyethylene bags in an HDPE drum with desiccant; long-term storage is controlled at 20–25 °C with excursions permitted to 15–30 °C according to ICH Q1A(R2) zones I and II. Retest intervals are assigned from formal stability data; no stability claim is made beyond the assigned retest date.

What Distinguishes the (1S,2S) Antipode from the Chloramphenicol Base and Racemic Mixtures?

The (1S,2S) configuration is the non-superimposable mirror image of the D-threo aminodiol used as the chloramphenicol nucleus. Published activity data for this antipode in chloramphenicol-like microbial protein-synthesis inhibition are limited; consequently, it is not qualified as a direct replacement in registered chloramphenicol routes. The racemic threo mixture and the erythro diastereomers differ in melting behaviour, optical rotation, chiral HPLC retention, and biological recognition. The free base also differs from the hydrochloride salt: the hydrochloride increases aqueous solubility through protonation, alters the weight-based assay, and may require different dissolution testing. Switching between free base and salt is not a 1:1 mass substitution; the molecular weight of the counterion and the specific analytical method must be corrected. In synthetic use, the (1S,2S) antipode provides access to the opposite enantiomeric series of oxazoline and amide derivatives.

Tablet and capsule development with this free base should first address the primary amine–reducing sugar incompatibility. Lactose monohydrate is a reducing sugar; in the presence of residual moisture and heat, Maillard-type browning with the aliphatic amine is a known stability risk under accelerated conditions of 40 °C / 75% RH per ICH Q1A(R2). Mannitol, dibasic calcium phosphate dihydrate, or microcrystalline cellulose are therefore preferred filler candidates when wet granulation or aqueous film coating is required. Direct compression on a rotary tablet press can proceed if the blend reaches acceptable flow; magnesium stearate at 0.5–1.0% (w/w) is added as a die-wall lubricant, and post-lubricant blending is limited to not more than 5 min to avoid over-lubrication and reduced tablet tensile strength. Blend uniformity is evaluated according to USP <905> or Ph. Eur. 2.9.40; content uniformity follows USP <905>. Hard gelatin or hypromellose capsule filling can be used when the powder plug or granulation meets fill weight variability; transparent capsule bodies may require light-protective packaging because of the nitrophenyl chromophore. Film coating with light-protective polymers is commonly required to limit photodegradation.

Release Specification Matrix for Oral and Injectable Grades

Dissolution method development for the free base requires pH-solubility profiling across the physiological pH range. Because the molecule is weakly basic, dissolution in simulated gastric fluid may be rapid if the drug substance is adequately wetted, while dissolution in pH 6.8 phosphate buffer may slow unless the formulation includes a pH modifier or a salt form. The choice between free base and a pharmaceutically acceptable salt should be based on aqueous solubility and intrinsic dissolution rate measured with a rotating-disk apparatus according to USP <1087>; published data for this specific stereoisomer are limited, and formulation decisions should not be transferred from the chloramphenicol base without confirmatory studies.

For enantiopurity assurance, chiral method development typically uses a polysaccharide-based chiral stationary phase with a mobile phase containing an organic modifier and a volatile acid or buffer. The nitrophenyl chromophore permits ultraviolet detection near 270–280 nm, although the exact wavelength is validated against the qualified reference standard. The method must separate the (1S,2S) isomer from the (1R,2R) antipode with resolution not less than 2.0, and from erythro diastereomers; system suitability also requires a relative standard deviation of peak area not more than 2.0% across replicate injections. The analytical procedure is validated for specificity, accuracy, precision, linearity, range, and robustness according to ICH Q2(R2).

Because residual solvents are process-dependent, headspace gas chromatography is used to quantify Class 1 and Class 2 solvents when process history indicates their use. If the synthesis uses methanol, the limit is 3000 ppm; if dichloromethane is used, the limit is 600 ppm; toluene is limited to 890 ppm. Class 3 solvents are reported for information and controlled collectively at 5000 ppm. For elemental impurities, the route-specific risk assessment under ICH Q3D evaluates Class 1, 2A, and 2B elements. Injectable-grade material may require lower limits for Cd, Pb, As, Hg, Co, V, and Ni than oral grade because the permissible daily exposures differ by route.

Under ICH Q1A(R2), Q1B, and Q1E, stability studies are designed to cover storage, handling, and light exposure. The free base is stored in light-resistant, tight containers; photostability testing under ICH Q1B is required because nitroaromatic systems can generate photodegradants that are absent in the non-irradiated sample. Forced degradation includes acid, base, oxidation, heat, and light stress; the resulting degradants are identified by HPLC-mass spectrometry and included in the related-substances method where relevant. No stability claim is made beyond the assigned retest period; users should monitor related substances and optical purity at each retest interval.

Because the material is an aromatic nitro compound, dry storage is required; the container should be kept tightly closed. Oxidizing agents and strong bases are avoided. Nitrite salts and nitrous acid are specifically excluded from the manufacturing area because nitrosamine formation may occur with the primary amine. Personnel handling the injectable grade should use dedicated scoops and sampling tools to prevent cross-contamination. As a fine organic powder, the micronized grade should be processed with appropriate grounding and inert-gas blanketing where dust explosion or electrostatic charging is a concern.

Granulation and drying should be designed around the API’s primary amine and nitroaromatic stability. If fluid-bed granulation is used, inlet-air dew point and product temperature are controlled to avoid premature glass transition of the binder and localised moisture segregation; drying end-point is confirmed by loss-on-drying and is not determined solely by outlet temperature. For wet granulation, non-reducing binders such as povidone or hypromellose are preferred; aldehyde-bearing binders or flavours are excluded because the primary amine can form Schiff bases. Extragranular disintegrant addition follows the same compatibility logic; croscarmellose sodium or sodium starch glycolate may be incorporated in compendial disintegrant ranges, but formulation-specific stability studies are required because trace reactive impurities can vary between grades. Roller compaction is an alternative dry granulation route when the powder has poor flow; ribbon density and mill screen size should be characterized against downstream tablet hardness and dissolution, with the latter evaluated by USP <711> dissolution apparatus selected according to the dosage form.

When the Injectable Grade Is Buffered in Aseptic Filling Operations

Injection-grade material is released with low bioburden and controlled endotoxin because the free base is not a sterile powder. The formulation is prepared by dissolving the API in water for injection with pH adjustment, typically with dilute hydrochloric acid, to protonate the aliphatic amine and achieve the target solution concentration. The exact pH and buffer species are selected from solubility and forced-degradation data; acetate and phosphate buffers are evaluated for buffer capacity, but pH values near the amine pKa can cause temperature-dependent solubility shifts. The bulk solution is passed through a 0.22 µm sterilising-grade membrane filter; process validation includes filter compatibility, extractables, and product hold time. Amber Type I glass vials are selected to protect the nitrophenyl chromophore from light. Bacterial endotoxin limits are calculated from the dose-based K/M formula, with a common intravenous K value of 5 EU/kg; for small-volume parenterals, particulate matter limits are 6000 particles ≥10 µm and 600 particles ≥25 µm per container, while large-volume parenterals are limited to 25 particles ≥10 µm and 3 particles ≥25 µm per millilitre. Bulk dry-heat sterilisation is avoided unless thermal stability of the critical quality attributes is demonstrated.

Injectable formulations based on this free base should include a terminal sterilization strategy only if the drug product stability data support moist-heat or aseptic processing. Given the primary amine group, combination with nitrite-containing excipients or nitrosating species is avoided; nitrosamine risk assessment is performed under ICH M7(R2) and regional nitrosamine control guidance. Compatibility with rubber stoppers and sealing materials is verified through extractable and leachable studies because the nitrophenyl group can absorb visible light and may generate photodegradants that should be monitored as specified degradation products. The substance is handled in GMP areas with relevant air classification; oral-grade and injectable-grade lots must not be interchanged without a documented bridging study.